Commentary|Articles|November 6, 2024

FDA Q&A: Addressing Biosimilar Safety, AI in Drug Development, and Supply Chain Challenges

In a Q&A, an FDA spokesperson discusses efforts to reduce misinformation about biosimilars through education, the agency’s collaboration with global regulators to streamline development, and its work to address drug shortages while emphasizing safety, efficacy, and public trust.

As the US unravels the results from the presidential election, a Q&A with an anonymous FDA spokesperson discusses efforts to reduce misinformation about biosimilars, emphasizing education and experience to build confidence in their safety. The FDA is also collaborating with international regulators to streamline biosimilar development and reduce costs, aiming to enhance global competition and accessibility. To build public trust, the FDA continues to educate the public on the rigorous approval process for biosimilars, ensuring they meet high safety standards.